The future of the artificial kidney: Moving towards wearable and miniaturized devices;Los dispositivos portátiles miniaturizados el futuro del riñón artificial

Nefrologia

Volumn 31, Issue 1, 2011, Pages 9-16

  Ronco, Claudio ^a   Davenport, A ^b   Gura, V ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL KIDNEY; CHRONIC KIDNEY FAILURE; ECONOMICS; EDEMA; ELECTRONICS; EQUIPMENT DESIGN; FORECASTING; HEALTH CARE DELIVERY; HEART FAILURE; HEMOFILTRATION; HUMAN; INSTRUMENTATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION;

EDEMA; EQUIPMENT DESIGN; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HEART FAILURE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY, ARTIFICIAL; MINIATURIZATION; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; ULTRAFILTRATION;

EID: 79951829930     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Nov.10758     Document Type: Article

References (42)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(Suppl 1):S37-40.
2. Lockridge RS Jr. Daily dialysis and long-term outcomes-the Lynchburg Nephrology NHHD experience. Nephrol News Issues 1999;13(12):16,19,23-6.
3. Ledebo I, Ronco C. The best dialysis therapy? Results from an international survey among nephrology professionals. NDT Plus 2008;1(6):403-8. Epub 2008 Sep 12.
4. Robinson BM, Port FK. International hemodialysis patient outcomes comparisons revisited: the role of practice patterns and other factors. Clin J Am Soc Nephrol 2009;4(Suppl 1):S12-7.
5. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Dialysis adequacy and health related quality of life in hemodialysis patients. ASAIO J 2002;48:565-9.
6. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: The dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003;64:339-49.
7. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional incenter hemodialysis. Kidney Int 2003;64:1004-11.
8. Mohr PE, Neumann PJ, Franco SJ, Marainen J, Lockridge R, Ting G. The case for daily dialysis: Its impact on costs and quality of life. Am J Kidney Dis 2001;37:777-89.
9. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis 2002;40:1013-22.
10. Lockridge RS Jr. The direction of end-stage renal disease reimbursement in the United States. Semin Dial 2004;17:125-30.
11. Lockridge RS Jr, McKinney JK. Is HCFA's reimbursement policy controlling quality of care for end-stage renal disease patients? ASAIO J 2001;47:466-8.
12. Ronco C, Davenport A, Gura V. Toward the wearable artificial kidney. Hemodial Int 2008;12(Suppl 1):S40-7.
13. Ronco C, Davenport A, Gura V. A wearable artificial kidney: dream or reality? Nat Clin Pract Nephrol 2008;4(11):604-5. Epub 2008 Sep 9.
14. Pierratos A. Daily hemodialysis: An update. Curr Opin Nephrol Hypertens 2002;11:165-71.
15. Lindsay RM, Heidenheim AP, Leitch R, et al. Short daily versus long nocturnal hemodialysis. ASAIO J 2001;47:449-55.
16. Buoncristiani U, Fagugli R, Quintaliani G, Kulurianu H. Rationale for daily dialysis. Home Hemodial Int 1997;1:12-8.
17. Depner T. Why daily hemodialysis is better: Solute kinetics. Semin Dial 1999;12:462-71.
18. Pierratos A. Effect of therapy time and frequency on effective solute removal. Semin Dial 2001;14:284-8.
19. Gura V, Beizai M, Ezon C, Polaschegg HD. Continuous renal replacement therapy for end-stage renal disease: The wearable artificial kidney (WAK). In: Ronco C, Brendolan A, Levin NW (eds.). Cardiovascular Disorders in Hemodialysis. Basel: Karger, Contrib Nephrol 2005;149:325-33.
20. Gura V, Beizai M, Ezon C. CRRT for CHF; the wearable continuous ultrafiltration system. ASAIO J 2006;52:59-61.
21. Gura V, Beizai M, Ezon C, Polaschegg HD. Pulsatile blood and dialysate counter phase flows, increased sorbent capacity and a high flux membrane explain the high efficiency of the wearable artificial kidney (WAK). J Am Soc Nephrol 2005;16:38A-39A.
22. Gura V, Ronco C, Nalesso F, Brendolan A, Beizai M, Ezon C, et al. A wearable haemofilter: first human study of slow continuous ambulatory ultrafiltration. Kidney Int 2008;73(4):497-502. Epub 2007 Dec 5.
23. Gura V, Beizai M, Ezon C, Snukal R, Rambod E. The wearable artificial kidney (WAK) removes beta2-microglobulins (B2M). J Am Soc Nephrol 2006;17:723A-724A.
24. Davenport A, Gura V, Ronco C, Beizai M, Ezon C, Rambod E. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet 2007;370(9604):2005-10.
25. Shettigar UR, Kablitz C, Stephen R, Kolff WJ. A portable hemodialysisLocatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: The dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003;64:339-49.
26. Shaldon S, Beau MC, Dschodt G, Lysaght MJ, Ramperez P, Mion C. Continuous ambulatory hemofiltration. Trans Am Soc Artif Intern Organs 1980;26:210-2.
27. Kolf WJ, Watschinger B, Vertes V. Wearable kidney: Results in patients treated with the coil kidney (disposable dialyzing unit). J Am Med Assoc 1956;161:1433-7.
28. Asaba H, Bergstrom J, Furst P, Shaldon S, Wiklund S. Treatment of diuretic resistant fluid retention with ultrafiltration. Acta Med Scand 1978;204:145-9.
29. Murisasco A, Reynier JP, Ragon A, Boobes Y, Baz M, Durand C, et al. Continuous arteriovenous hemofiltration in a wearable device to treat end stage renal disease. Trans Am Soc Artif Intern Organs 1986;32:567-71.
30. Neff MS, Sadjadi S, Slifkin R. A wearable artificial glomerulus. Trans Am Soc Artif Intern Organs 1979;25:71-3.
31. Hillege HL, Girbes ARJ, De Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
32. Davenport A. Ultrafiltration in diuretic-resistant volume overload in nephritic syndrome and patients with ascites due to chronic liver disease. Cardiology 2001;96:190-5.
33. Kramer P, Schrader J, Bohnsack W, Grieben G, Grove HJ, Scheter F. Continuous arteriovenous hemofiltration. Proc Eur Dial Transplant Assoc 1981;18:743-9.
34. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al, UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
35. Davenport A, Mehta S The acute Dialysis Quality Initiative-part VI: access and anticoagulation in CRRT. Adv Ren Replace Ther 2002;9:273-81.
36. Palevsky PM, Baldwin I, Davenport A, Goldstein S, Paganini E. Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. Curr Opin Crit Care 2005;11:548-54.
37. Davenport A, Will EJ, Davison AM. The effect of the direction of dialysate flow on the efficiency of CAVHD. Blood Purif 1990;8:329-36.
38. Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, et al, HEMO Study Group. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:69-77.
39. Ronco C, Fecondini L. The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif 2007;25(4):383-8. Epub 2007 Sep 3.
40. Ronco C. The wearable artificial kidney: is peritoneal dialysis the solution? Contrib Nephrol 2009;163:300-5. Epub 2009 Jun 3.
41. House AA, Ronco C. Extracorporeal blood purification in sepsis and sepsis-related acute kidney injury. Blood Purif 2008;26(1):30-5. Epub 2008 Jan 10.
42. Cruz D, Bellomo R, Kellum JA, De Cal M, Ronco C. The future of extracorporeal support. Crit Care Med 2008;36(4 Suppl):S243-52.